Wook-Bum Pyun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5447559/publications.pdf

Version: 2024-02-01

40 831 14 28 papers citations h-index g-index

43 43 43 1466
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clinical Hypertension, 2019, 25, 20.	2.0	193
2	Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea. European Heart Journal, 2017, 38, 2599-2607.	2.2	108
3	2018 Korean Society of Hypertension guidelines for the management of hypertension: part I-epidemiology of hypertension. Clinical Hypertension, 2019, 25, 16.	2.0	69
4	2013 Korean Society of Hypertension guidelines for the management of hypertension: part l–epidemiology and diagnosis of hypertension. Clinical Hypertension, 2015, 21, 1.	2.0	64
5	SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World (SUGAR): A Multi-Center, Retrospective, Observational Study. PLoS ONE, 2014, 9, e86596.	2.5	33
6	2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations. Clinical Hypertension, $2019, 25, 19$.	2.0	31
7	2013 Korean Society of Hypertension guidelines for the management of hypertension. Part llâ€"treatments of hypertension. Clinical Hypertension, 2015, 21, 2.	2.0	30
8	Smartphone / smartwatch-based cuffless blood pressure measurement : a position paper from the Korean Society of Hypertension. Clinical Hypertension, 2021, 27, 4.	2.0	27
9	Prognostic implications of late gadolinium enhancement at the right ventricular insertion point in patients with non-ischemic dilated cardiomyopathy: A multicenter retrospective cohort study. PLoS ONE, 2018, 13, e0208100.	2.5	26
10	Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients. Korean Circulation Journal, 2015, 45, 225.	1.9	23
11	Clinical Benefit of Treatment of Stage-1, Low-Risk Hypertension. Hypertension, 2018, 72, 1285-1293.	2.7	20
12	Dose-Dependent Cardioprotection of Moderate (32°C) Versus Mild (35°C) Therapeutic Hypothermia in Porcine AcuteÂMyocardial Infarction. JACC: Cardiovascular Interventions, 2018, 11, 195-205.	2.9	19
13	Antihypertensive Drugs and the Risk of Cancer: A Nationwide Cohort Study. Journal of Clinical Medicine, 2021, 10, 771.	2.4	16
14	Differential Control Rate of Systolic and Diastolic Blood Pressure among Korean Adults with Hypertension: the Sixth Korean National Health and Nutrition Examination Survey, 2013–2015 (KNHANES VI). Korean Circulation Journal, 2019, 49, 1035.	1.9	15
15	Efficacy and Safety of 30-Mg Fimasartan for the Treatment of Patients With Mild to Moderate Hypertension: An 8-Week, Multicenter, Randomized, Double-Blind, Phase III Clinical Study. Clinical Therapeutics, 2014, 36, 1412-1421.	2.5	14
16	Intensive blood pressure lowering: a practical review. Clinical Hypertension, 2020, 26, 21.	2.0	13
17	Association between Central Obesity and Circadian Parameters of Blood Pressure from the Korean Ambulatory Blood Pressure Monitoring Registry: Kor-ABP Registry. Journal of Korean Medical Science, 2013, 28, 1461.	2.5	12
18	Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?. Clinical Hypertension, 2020, 26, 11.	2.0	12

#	Article	IF	Citations
19	Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. Clinical Therapeutics, 2019, 41, 233-248.e9.	2.5	11
20	Poor Health-Related Quality of Life and Proactive Primary Control Strategy May Act as Risk Factors for Acute Coronary Syndrome. Korean Circulation Journal, 2015, 45, 117.	1.9	10
21	Therapeutic Hypothermia for Cardioprotection in Acute Myocardial Infarction. Yonsei Medical Journal, 2016, 57, 291.	2.2	10
22	Prevalence of resistant hypertension and associated factors for blood pressure control status using Korean ambulatory blood pressure monitoring registry data. Clinical Hypertension, 2016, 22, 8.	2.0	10
23	Clinical features and predictors of masked uncontrolled hypertension from the Korean Ambulatory Blood Pressure Monitoring Registry. Korean Journal of Internal Medicine, 2021, 36, 1102-1114.	1.7	9
24	Higher Blood Pressure Variability in White Coat Hypertension; from the Korean Ambulatory Blood Pressure Monitoring Registry. Korean Circulation Journal, 2016, 46, 365.	1.9	8
25	Suboptimal Management Status of Younger Hypertensive Population in Korea. Korean Circulation Journal, 2021, 51, 598.	1.9	8
26	Effect of angiotensin receptor blockers on the development of cancer: A nationwide cohort study in korea. Journal of Clinical Hypertension, 2021, 23, 879-887.	2.0	7
27	Effect of Short-Term Exposure to Fine Particulate Matter and Temperature on Acute Myocardial Infarction in Korea. International Journal of Environmental Research and Public Health, 2021, 18, 4822.	2.6	6
28	Protective effect of controlled blood pressure on risk of dementia in low-risk, grade 1 hypertension. Journal of Hypertension, 2021, 39, 1662-1669.	0.5	5
29	Clinical impact of pre-hypertension on the risk of cancer in male and female subjects. Scientific Reports, 2020, 10, 9974.	3.3	4
30	Hypertension Control in Young Population: the Earlier, the Better. Korean Circulation Journal, 2020, 50, 1092.	1.9	4
31	Comparative effect on platelet function of a fixed-dose aspirin and clopidogrel combination versus separate formulations in patients with coronary artery disease: A phase IV, multicenter, prospective, 4-week non-inferiority trial. International Journal of Cardiology, 2016, 202, 331-335.	1.7	3
32	Lifestyle Modification, the Effective but Neglected Strategy in Lowering Blood Pressure. Korean Circulation Journal, 2018, 48, 652.	1.9	3
33	Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial. Trials, 2019, 20, 389.	1.6	3
34	Elevated On-Treatment Diastolic Blood Pressure and Cardiovascular Outcomes in the Presence of Achieved Systolic Blood Pressure Targets. Korean Circulation Journal, 2022, 52, 460.	1.9	3
35	Are Statins Beneficial for Patients With Heart Failure?. Korean Circulation Journal, 2008, 38, 185.	1.9	1
36	Subclinical Hypothyroidism or Thyroid Autoimmunity and Variant Angina: By Chance? or with a Chance?. Korean Circulation Journal, 2015, 45, 106.	1.9	1

#	Article	lF	CITATIONS
37	Life Threatening Complication of Self-made Remedy for Controlling High Blood Pressure-Coronary Artery Vasospasm Associated with latrogenic Thyrotoxicosis. Korean Circulation Journal, 2016, 46, 870.	1.9	O
38	Transition of May Measurement Month to an online hypertension awareness campaign in Korea during the COVID-19 pandemic. European Heart Journal Digital Health, 0, , .	1.7	O
39	A Randomized, Double-blind, Active-controlled, Two Parallel-Group, Optional Titration, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without a Diuretic Combination in Elderly Patients With Essential Hypertension. Clinical Therapeutics. 2021, 43, 1746-1756.	2.5	O
40	Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labeled Pilot Clinical Study. Frontiers in Cardiovascular Medicine, 2021, 8, 765081.	2.4	0